A carregar...
A dose‐ranging study of ticagrelor in children aged 3‐17 years with sickle cell disease: A 2‐part phase 2 study
Antiplatelet treatment is a potential therapeutic approach for sickle cell disease (SCD). Ticagrelor inhibits platelet aggregation and is approved for adults with acute coronary syndrome and following myocardial infarction. HESTIA1 (NCT02214121) was a 2‐part, phase 2 dose‐finding study generating ti...
Na minha lista:
| Publicado no: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282821/ https://ncbi.nlm.nih.gov/pubmed/30187935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25273 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|